{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:33:34Z","timestamp":1794018814329,"version":"4.8.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013290","name":"National Key Research and Development Program of China Stem Cell and Translational Research","doi-asserted-by":"crossref","award":["2018YFC1200100"],"award-info":[{"award-number":["2018YFC1200100"]}],"id":[{"id":"10.13039\/501100013290","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013290","name":"National Key Research and Development Program of China Stem Cell and Translational Research","doi-asserted-by":"crossref","award":["2018YFC1200105"],"award-info":[{"award-number":["2018YFC1200105"]}],"id":[{"id":"10.13039\/501100013290","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["grant no. 2016-I2M-3\u2013014"],"award-info":[{"award-number":["grant no. 2016-I2M-3\u2013014"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Antimicrob Resist Infect Control"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study reports the global trends of antimicrobial susceptibility to ceftaroline and ceftazidime\u2013avibactam using data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program between 2012 and 2016.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>For the 2012\u20132016 ATLAS program, 205 medical centers located in Africa-Middle East (n\u2009=\u200912), Asia\u2013Pacific (n\u2009=\u200932), Europe (n\u2009=\u200994), Latin America (n\u2009=\u200926), North America (n\u2009=\u200931), and Oceania (n\u2009=\u200910) consecutively collected the clinical isolates. The minimum inhibitory concentrations (MICs) and in vitro susceptibilities to ceftaroline and ceftazidime\u2013avibactam were assessed using the Clinical and Laboratory Standards Institute (CLSI) 2019and European Committee on Antimicrobial Susceptibility Testing (EUCAST) 2019 guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between 2012 and 2016, 176,345 isolates were collected from around the globe and included in the analysis. Regarding Gram-negative bacteria, ceftazidime\u2013avibactam demonstrated high susceptibility (&gt;\u200990%) against\n                      <jats:italic>Enterobacteriaceae<\/jats:italic>\n                      and\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      , with increased antimicrobial activity observed from the addition of avibactam (4\u00a0mg\/L) to ceftazidime. Regarding Gram-positive bacteria, ceftaroline showed &gt;\u200990% susceptibility against\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      ,\n                      <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n                      , \u03b1-and \u03b2-hemolytic\n                      <jats:italic>Streptococcus<\/jats:italic>\n                      . The antimicrobial susceptibilities to ceftaroline and ceftazidime\u2013avibactam were mostly stable from 2012 to 2016, but the susceptibilities to ceftazidime\u2013avibactam to carbapenem-resistant (CR)\n                      <jats:italic>Klebsiella pneumonia<\/jats:italic>\n                      (88.4\u201381.6%) and to CR-\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                      (89.6\u201372.7%) decreased over time. In terms of regional difference, the susceptibilities of methicillin-resistant\n                      <jats:italic>S. aureus<\/jats:italic>\n                      to ceftaroline in Asia and of CR-\n                      <jats:italic>K. pneumonia<\/jats:italic>\n                      to ceftazidime\u2013avibactam in Asia\/Africa-Middle East were lower compared with other regions, while the susceptibility of CR-\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                      to ceftazidime\u2013avibactam in North America was higher.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The addition of avibactam improves the activity of ceftazidime against\n                      <jats:italic>Enterobacteriaceae<\/jats:italic>\n                      and\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                      . The global antimicrobial susceptibilities to ceftaroline and ceftazidime\u2013avibactam were, in general, stable from 2012 to 2016, but a marked reduction in the susceptibilities of specific species and CR-\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                      to ceftazidime\u2013avibactam was observed.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13756-020-00829-z","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T07:03:50Z","timestamp":1603782230000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime\u2013avibactam: a surveillance study from the ATLAS program (2012\u20132016)"],"prefix":"10.1186","volume":"9","author":[{"given":"Hui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeng","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiwen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,27]]},"reference":[{"key":"829_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.micpath.2016.02.009","volume":"95","author":"B Khameneh","year":"2016","unstructured":"Khameneh B, Diab R, Ghazvini K, Fazly Bazzaz BS. Breakthroughs in bacterial resistance mechanisms and the potential ways to combat them. Microb Pathog. 2016;95:32\u201342.","journal-title":"Microb Pathog"},{"issue":"23","key":"829_CR2","doi-asserted-by":"publisher","first-page":"6600","DOI":"10.1002\/anie.201506818","volume":"55","author":"MF Chellat","year":"2016","unstructured":"Chellat MF, Raguz L, Riedl R. Targeting antibiotic resistance. Angew Chem. 2016;55(23):6600\u201326.","journal-title":"Angew Chem"},{"key":"829_CR3","volume-title":"Methicillin resistant Staphylococcus aureus (MRSA)","author":"AH Siddiqui","year":"2019","unstructured":"Siddiqui AH, Koirala J. Methicillin resistant Staphylococcus aureus (MRSA). Treasure Island: StatPearls; 2019."},{"issue":"3","key":"829_CR4","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1080\/21505594.2016.1159366","volume":"7","author":"M Akova","year":"2016","unstructured":"Akova M. Epidemiology of antimicrobial resistance in bloodstream infections. Virulence. 2016;7(3):252\u201366.","journal-title":"Virulence"},{"issue":"3","key":"829_CR5","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318\u201327.","journal-title":"Lancet Infect Dis"},{"key":"829_CR6","first-page":"35","volume":"9","author":"J Chipolombwe","year":"2016","unstructured":"Chipolombwe J, Torok ME, Mbelle N, Nyasulu P. Methicillin-resistant Staphylococcus aureus multiple sites surveillance: a systemic review of the literature. Infect Drug Resist. 2016;9:35\u201342.","journal-title":"Infect Drug Resist"},{"issue":"4","key":"829_CR7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jiph.2016.08.007","volume":"10","author":"M Frieri","year":"2017","unstructured":"Frieri M, Kumar K, Boutin A. Antibiotic resistance. J Infect Public Health. 2017;10(4):369\u201378.","journal-title":"J Infect Public Health"},{"issue":"Suppl 1","key":"829_CR8","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1093\/ofid\/ofy346","volume":"6","author":"AS Fuhrmeister","year":"2019","unstructured":"Fuhrmeister AS, Jones RN. The importance of antimicrobial resistance monitoring worldwide and the origins of SENTRY antimicrobial surveillance program. Open Forum Infect Dis. 2019;6(Suppl 1):S1\u20134.","journal-title":"Open Forum Infect Dis"},{"key":"829_CR9","first-page":"1","volume":"3","author":"C Duplessis","year":"2011","unstructured":"Duplessis C, Crum-Cianflone NF. Ceftaroline: a new cephalosporin with activity against methicillin-resistant Staphylococcus aureus (MRSA). Clin Med Rev Ther. 2011;3:1\u201317.","journal-title":"Clin Med Rev Ther"},{"issue":"1","key":"829_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11096-016-0417-z","volume":"39","author":"MS El Hajj","year":"2017","unstructured":"El Hajj MS, Turgeon RD, Wilby KJ. Ceftaroline fosamil for community-acquired pneumonia and skin and skin structure infections: a systematic review. Int J Clin Pharm. 2017;39(1):26\u201332.","journal-title":"Int J Clin Pharm"},{"issue":"9","key":"829_CR11","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/S1473-3099(15)00139-5","volume":"15","author":"SA Pawluk","year":"2015","unstructured":"Pawluk SA, Wilby KJ. Ceftaroline fosamil for community-acquired pneumonia. Lancet Infect Dis. 2015;15(9):999.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"829_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40121-014-0036-8","volume":"3","author":"JJ Carreno","year":"2014","unstructured":"Carreno JJ, Lodise TP. Ceftaroline fosamil for the treatment of community-acquired pneumonia: from focus to capture. Infect Dis Ther. 2014;3(2):123\u201332.","journal-title":"Infect Dis Ther"},{"key":"829_CR13","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2147\/TCRM.S75412","volume":"11","author":"MA Mpenge","year":"2015","unstructured":"Mpenge MA, MacGowan AP. Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia. Ther Clin Risk Manag. 2015;11:565\u201379.","journal-title":"Ther Clin Risk Manag"},{"issue":"29","key":"829_CR14","doi-asserted-by":"publisher","first-page":"11663","DOI":"10.1073\/pnas.1205073109","volume":"109","author":"DE Ehmann","year":"2012","unstructured":"Ehmann DE, Jahic H, Ross PL, et al. Avibactam is a covalent, reversible, non-beta-lactam beta-lactamase inhibitor. Proc Natl Acad Sci USA. 2012;109(29):11663\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"829_CR15","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s40265-018-0902-x","volume":"78","author":"M Shirley","year":"2018","unstructured":"Shirley M. Ceftazidime\u2013avibactam: a review in the treatment of serious gram-negative bacterial infections. Drugs. 2018;78(6):675\u201392.","journal-title":"Drugs"},{"key":"829_CR16","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 29th ed. CLSI supplement M100. Wayne, PA: CLSI; 2019."},{"key":"829_CR17","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0. 2019. https:\/\/www.eucast.org\/clinical_breakpoints\/. Accessed 2 Jan 2019."},{"issue":"suppl_2","key":"829_CR18","doi-asserted-by":"publisher","first-page":"S206","DOI":"10.1093\/cid\/ciy659","volume":"67","author":"M Zhou","year":"2018","unstructured":"Zhou M, Chen J, Liu Y, et al. In vitro activities of Ceftaroline\/Avibactam, Ceftazidime\/Avibactam, and other comparators against pathogens from various complicated infections in China. Clin Infect Dis. 2018;67(suppl_2):S206\u201316.","journal-title":"Clin Infect Dis"},{"key":"829_CR19","doi-asserted-by":"crossref","unstructured":"Karlowsky JA, Kazmierczak KM, Bouchillon SK, de Jonge BLM, Stone GG, Sahm DF. In vitro activity of ceftazidime\u2013avibactam against clinical isolates of enterobacteriaceae and Pseudomonas aeruginosa collected in Asia-Pacific countries: results from the INFORM Global Surveillance Program, 2012 to 2015. Antimicrob Agents Chemother. 2018; 62(7):e02569\u201317.","DOI":"10.1128\/AAC.02569-17"},{"issue":"Suppl 3","key":"829_CR20","first-page":"iii69","volume":"66","author":"RN Jones","year":"2011","unstructured":"Jones RN, Farrell DJ, Mendes RE, Sader HS. Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study. J Antimicrob Chemother. 2011;66(Suppl 3):iii69-80.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"829_CR21","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1128\/AAC.02794-15","volume":"60","author":"HS Sader","year":"2016","unstructured":"Sader HS, Flamm RK, Mendes RE, Farrell DJ, Jones RN. Antimicrobial activities of ceftaroline and comparator agents against bacterial organisms causing bacteremia in patients with skin and skin structure infections in U.S. Medical Centers, 2008 to 2014. Antimicrob Agents Chemother. 2016;60(4):2558\u201363.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"829_CR22","doi-asserted-by":"publisher","first-page":"353","DOI":"10.4037\/aacnacc2016612","volume":"27","author":"KA Connor","year":"2016","unstructured":"Connor KA. Newer intravenous antibiotics in the intensive care unit: ceftaroline, ceftolozane\u2013tazobactam, and ceftazidime\u2013avibactam. AACN Adv Crit Care. 2016;27(4):353\u20137.","journal-title":"AACN Adv Crit Care"},{"issue":"10","key":"829_CR23","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1093\/jac\/dky267","volume":"73","author":"KM Kazmierczak","year":"2018","unstructured":"Kazmierczak KM, de Jonge BLM, Stone GG, Sahm DF. In vitro activity of ceftazidime\/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012\u201315. J Antimicrob Chemother. 2018;73(10):2777\u201381.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"829_CR24","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1128\/AAC.04614-14","volume":"59","author":"HS Sader","year":"2015","unstructured":"Sader HS, Flamm RK, Streit JM, Farrell DJ, Jones RN. Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program. Antimicrob Agents Chemother. 2015;59(4):2458\u201361.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"829_CR25","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.diagmicrobio.2016.07.012","volume":"86","author":"JA Karlowsky","year":"2016","unstructured":"Karlowsky JA, Biedenbach DJ, Bouchillon SK, Hackel M, Iaconis JP, Sahm DF. In vitro activity of Ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in African and Middle Eastern countries: AWARE global surveillance program 2012\u20132014. Diagn Microbiol Infect Dis. 2016;86(2):194\u20139.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"829_CR26","doi-asserted-by":"publisher","first-page":"114843","DOI":"10.1016\/j.diagmicrobio.2019.05.015","volume":"95","author":"IG Bae","year":"2019","unstructured":"Bae IG, Stone GG. Activity of ceftaroline against pathogens associated with community-acquired pneumonia collected as part of the AWARE surveillance program, 2015\u20132016. Diagn Microbiol Infect Dis. 2019;95:114843.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl 3","key":"829_CR27","doi-asserted-by":"publisher","first-page":"S194","DOI":"10.1093\/cid\/cis562","volume":"55","author":"RK Flamm","year":"2012","unstructured":"Flamm RK, Sader HS, Farrell DJ, Jones RN. Ceftaroline potency among 9 US Census regions: report from the 2010 AWARE Program. Clin Infect Dis. 2012;55(Suppl 3):S194-205.","journal-title":"Clin Infect Dis"},{"key":"829_CR28","doi-asserted-by":"publisher","first-page":"k462","DOI":"10.1136\/bmj.k462","volume":"360","author":"S Mayor","year":"2018","unstructured":"Mayor S. First WHO antimicrobial surveillance data reveal high levels of resistance globally. BMJ. 2018;360:k462.","journal-title":"BMJ"},{"key":"829_CR29","unstructured":"World Health Organization. Global Antimicrobial Resistance Surveillance System (GLASS) report: early implementation 2016\u201317. 2017. https:\/\/apps.who.int\/iris\/bitstream\/10665\/259744\/1\/9789241513449-eng.pdf?ua=1. Retrieved August 21, 2019. Geneva: World Health Organization; 2017."},{"key":"829_CR30","volume-title":"Antimicrobial resistance in the Asia Pacific region: a development agenda","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Antimicrobial resistance in the Asia Pacific region: a development agenda. Geneva: World Health Organization; 2017."},{"issue":"1","key":"829_CR31","doi-asserted-by":"publisher","first-page":"1483637","DOI":"10.1080\/16549716.2018.1483637","volume":"11","author":"M Kakkar","year":"2018","unstructured":"Kakkar M, Chatterjee P, Chauhan AS, et al. Antimicrobial resistance in South East Asia: time to ask the right questions. Glob Health Action. 2018;11(1):1483637.","journal-title":"Glob Health Action"},{"key":"829_CR32","doi-asserted-by":"publisher","first-page":"j3393","DOI":"10.1136\/bmj.j3393","volume":"358","author":"F Chereau","year":"2017","unstructured":"Chereau F, Opatowski L, Tourdjman M, Vong S. Risk assessment for antibiotic resistance in South East Asia. BMJ. 2017;358:j3393.","journal-title":"BMJ"},{"issue":"4","key":"829_CR33","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ijantimicag.2011.01.009","volume":"37","author":"SS Jean","year":"2011","unstructured":"Jean SS, Hsueh PR. High burden of antimicrobial resistance in Asia. Int J Antimicrob Agents. 2011;37(4):291\u20135.","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"829_CR34","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1473-3099(10)70143-2","volume":"10","author":"KK Kumarasamy","year":"2010","unstructured":"Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010;10(9):597\u2013602.","journal-title":"Lancet Infect Dis"},{"key":"829_CR35","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s13756-018-0441-y","volume":"7","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Chen M, Yu Y, Pan S, Liu Y. Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012\u20132016 as part of the Tigecycline Evaluation and Surveillance Trial. Antimicrob Resist Infect Control. 2018;7:152.","journal-title":"Antimicrob Resist Infect Control"},{"key":"829_CR36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jgar.2018.10.011","volume":"17","author":"TF O'Brien","year":"2019","unstructured":"O\u2019Brien TF, Clark A, Peters R, Stelling J. Why surveillance of antimicrobial resistance needs to be automated and comprehensive. J Glob Antimicrob Resist. 2019;17:8\u201315.","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"829_CR37","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/s41467-019-08853-3","volume":"10","author":"RS Hendriksen","year":"2019","unstructured":"Hendriksen RS, Munk P, Njage P, et al. Global monitoring of antimicrobial resistance based on metagenomics analyses of urban sewage. Nat Commun. 2019;10(1):1124.","journal-title":"Nat Commun"},{"issue":"12","key":"829_CR38","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/S1473-3099(13)70318-9","volume":"13","author":"R Laxminarayan","year":"2013","unstructured":"Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance-the need for global solutions. Lancet Infect Dis. 2013;13(12):1057\u201398.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"829_CR39","doi-asserted-by":"publisher","first-page":"169","DOI":"10.4103\/2229-3485.159943","volume":"6","author":"P Ranganathan","year":"2015","unstructured":"Ranganathan P, Pramesh CS, Buyse M. Common pitfalls in statistical analysis: clinical versus statistical significance. Perspect Clin Res. 2015;6(3):169\u201370.","journal-title":"Perspect Clin Res"},{"issue":"5","key":"829_CR40","first-page":"726","volume":"9","author":"P Page","year":"2014","unstructured":"Page P. Beyond statistical significance: clinical interpretation of rehabilitation research literature. Int J Sports Phys Ther. 2014;9(5):726\u201336.","journal-title":"Int J Sports Phys Ther"}],"container-title":["Antimicrobial Resistance &amp; Infection Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-020-00829-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13756-020-00829-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-020-00829-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T19:39:19Z","timestamp":1635277159000},"score":1,"resource":{"primary":{"URL":"https:\/\/aricjournal.biomedcentral.com\/articles\/10.1186\/s13756-020-00829-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,27]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["829"],"URL":"https:\/\/doi.org\/10.1186\/s13756-020-00829-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-31962\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-31962\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-31962\/v1","asserted-by":"object"}]},"ISSN":["2047-2994"],"issn-type":[{"value":"2047-2994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,27]]},"assertion":[{"value":"28 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare that they have no conflict of interest and have submitted the ICMJE Form for disclosure of potential conflicts of interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"166"}}